Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Genevant Sciences GmbH is currently managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, indicating that each pending matter is being reviewed by a different official. The involvement of 3 distinct art units shows that the company's current prosecution workload is spread across several technical divisions within the biotechnology sector.
ARNOLD, ERNST V is identified as the busiest examiner for the portfolio, with 1 busiest examiner pending action. Given that there are 4 pending office actions and 4 distinct examiners, each examiner is currently handling 1 action. This distribution, combined with the 3 distinct art units, suggests a decentralized prosecution environment. Practitioners must coordinate across various examiners and 3 distinct art units, requiring a strategy that can adapt to the different standards of three separate technical groups. The data reflects a broad and multi-faceted approach to the company's current patenting activities.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.9% |
| KELLY, ROBERT M | 1 | 74.1% | +24.6% |
| HASAN, KHALEDA B | 1 | 59.4% | +49.5% |
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18015398 | LIPID NANOPARTICLES FOR DELIVERING THERAPEUTICS TO LUNGS | HASAN, KHALEDA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17771421 | ORNITHINE TRANSCARBAMYLASE (OTC) CONSTRUCTS AND METHODS OF USING THE SAME | MARVICH, MARIA | 63d |
| 18832438 | POLY(ALKYLOXAZOLINE)-LIPID CONJUGATES AND LIPID PARTICLES CONTAINING SAME | ARNOLD, ERNST V | — |
| 18586033 | BLOCK COPOLYMERS | KELLY, ROBERT M | — |
| 18015398 | LIPID NANOPARTICLES FOR DELIVERING THERAPEUTICS TO LUNGS | HASAN, KHALEDA B | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1636 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18832438 | POLY(ALKYLOXAZOLINE)-LIPID CONJUGATES AND LIPID PARTICLES CONTAINING SAME | ARNOLD, ERNST V | — | §103§112DP | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18586033 | BLOCK COPOLYMERS | KELLY, ROBERT M | 1638 | §112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18015398 | LIPID NANOPARTICLES FOR DELIVERING THERAPEUTICS TO LUNGS | HASAN, KHALEDA B | 1636 | §102§103§112 | Non-Final OA | — | Pending | Jan 10, 2023 |
| 17771421 | ORNITHINE TRANSCARBAMYLASE (OTC) CONSTRUCTS AND METHODS OF USING THE SAME | MARVICH, MARIA | 1634 | §103§112DPOther | Final Rejection | 63d | Pending | Apr 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial